 | Info
Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
 | Out-
side |
| | | | |
|
| | | | |
Result : Searchterm 'Drug Information' found in 0 term [ ] and 28 definitions [ ]
| | 1 - 5 (of 28) nextResult Pages : [1 2 3 4 5 6] |  | |  | Searchterm 'Drug Information' was also found in the following services: | | | | |
| |  |
| |
|
ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325 |
| DEVELOPER |
EPIX Pharmaceuticals, Inc.
|
| CENTRAL MOIETY |
Gd2+ |
| CONTRAST EFFECT |
T1, predominantly positive enhancement |
| RELAXIVITY |
20-45 mmol-1sec-1, Bo=0,47T |
| PHARMACOKINETIC |
Intravascular |
| OSMOLALITY |
825 mOsmol/kg H2O |
| CONCENTRATION |
244 mg/mL, 0.25mmol/mL |
| DOSAGE |
0.12 mL/kg, 0.03 mmol/kg |
| PREPARATION |
ready to use |
| INDICATION |
Contrast enhanced magnetic resonance angiography |
| DEVELOPMENT STAGE |
FDA approved |
| DISTRIBUTOR |
See below |
| PRESENTATION |
10 mL vials |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
| | | | | | • Share the entry 'ABLAVAR™':    | | |
• View the NEWS results for 'ABLAVAR™' (1).
| | | | |  Further Reading: | Basics:
|
|
| |
| | | | | |
| |
|
This superparamagnetic oral contrast agent consists of large iron oxide particles, coated with insoluble material. Abdoscan® particles have a mean diameter no less than 300 nm. Gastrointestinal superparamagnetic contrast agents are used for negative bowel enhancement.
Abdoscan® was approved in Europe but was taken off the market in 2000, and all sales stopped by the end of 2002.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Ferristene (USAN) oral magnetic particles (OMP) |
| DEVELOPER |
Amersham |
| CENTRAL MOIETY |
Fe2+/Fe3+ |
| CONTRAST EFFECT |
T2*, predominantly negative enhancement |
| RELAXIVITY |
T2 |
| PHARMACOKINETIC |
Gastrointestinal |
| CONCENTRATION |
23.4 Fe/200ml |
| PREPARATION |
Dissolve |
| INDICATION |
Bowel marking |
| DEVELOPMENT STAGE |
Not FDA approved |
| PRESENTATION |
Bags with powder |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
| | | |
• View the DATABASE results for 'Abdoscan®' (2).
| | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200).
Artirem® has to be injected directly into the joints for better visualization and delimitation, of the ligament and tendon structures in particular.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Gadoterate meglumine, Gd-DOTA |
| DEVELOPER |
Guerbet S.A. |
| CENTRAL MOIETY |
Gd2+ |
| CONTRAST EFFECT |
T1, Predominantly positive enhancement |
| RELAXIVITY |
r1=3.4, r2=4.8, B0=1.0T |
| PHARMACOKINETIC |
Intravascular, extracellular, renal excretion |
| CONCENTRATION |
0,0025 mmol/ml |
| PREPARATION |
Finished product |
| INDICATION |
Arthrography |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Pre-filled syringes of 20 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
| | | |
• View the DATABASE results for 'Artirem®' (4).
| | | | |
| | | Searchterm 'Drug Information' was also found in the following services: | | | | |
| | |
| |
|
An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and will be developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours.
At this time the development of Clariscan™ is discontinued.
See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Feruglose, PEG-feron, USPIO, NC100150
|
| DEVELOPER |
Amersham Health |
| CENTRAL MOIETY |
Fe |
| CONTRAST EFFECT |
T2, Predominantly negative enhancement |
| RELAXIVITY |
R1=20, R2=35, B0=0.5T |
| PHARMACOKINETIC |
Intravascular |
| OSMOLALITY |
|
| CONCENTRATION |
29.8 mg Fe/mL |
| PREPARATION |
Suspend in an isotonic glucose solution |
| INDICATION |
Cardiovascular |
| DEVELOPMENT STAGE |
? |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
| | | |
• View the DATABASE results for 'Clariscan™' (6).
| | | | | | Further Reading: | Basics:
|
|
| |
| | | | | |
| |
|
Combidex® is the brand name (same as Sinerem®) for an ultrasmall superparamagnetic iron oxide (USPIO) in the development pipeline to detect metastatic disease in lymph nodes. Metastatic lymph nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes. Combidex® has also potential to be used as a functional molecular imaging agent.
In March 2005, AMAG Pharmaceuticals Inc received an approvable letter from the U.S. Food and Drug Administration with respect to Combidex subject to certain conditions.
See also Ferumoxtran, Drug Development and Approval Process USA, Molecular Imaging and Classifications, Characteristics, etc.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Ferumoxtran, USPIO, AMI-227 |
| DEVELOPER |
AMAG Pharmaceuticals, Inc. |
| CENTRAL MOIETY |
Fe3+/Fe2+ |
| CONTRAST EFFECT |
T1, predominantly T2 |
| RELAXIVITY |
r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T |
| PHARMACOKINETIC |
Vascular, lymph v. hepatocyte (AG-USPIO) |
| OSMOLALITY |
|
| CONCENTRATION |
|
| DOSAGE |
2.6 mg Fe/kg |
| PREPARATION |
Suspend in an isotonic glucose solution |
| INDICATION |
Lymph node, (MR angiography vascular, staging of RES-directed liver diseases) |
| DEVELOPMENT STAGE |
|
| DISTRIBUTOR |
|
| PRESENTATION |
|
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
| | | |
• View the DATABASE results for 'Combidex®' (6).
| | |
• View the NEWS results for 'Combidex®' (1).
| | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | |
| | | 1 - 5 (of 28) nextResult Pages : [1 2 3 4 5 6] |
| |
|
| |
 | Look
Ups |
| |
Random Page
top
